The Clinical Effect of Oral Vitamin D2 Supplementation on Psoriasis: A Double-Blind, Randomized, Placebo-Controlled Study
Table 1
Baseline characteristics between the vitamin D and placebo groups.
Characteristics
Vitamin D2 N=23
Placebo N=22
p-value
Gender, n(%)
Female
13(56.5%)
11(50.0%)
0.77
Male
10(43.5%)
11(50.0%)
Age
52.39±14.19
49.41±15.92
0.51
BMI
26.30±5.20
24.9±4.78
0.36
Fitzpatrick skin type
1
Type 4
12(52.17%)
11(50%)
Type 5
11(47.83%)
11(50%)
Underlying disease
Diabetes mellitus, n(%)
5(21.7%)
5(22.7%)
1.00
Hypertension, n(%)
7(30.4%)
11(50.0%)
0.23
Dyslipidemia, n(%)
7(30.4%)
6(27.3%)
1.00
Medications
Tar, n(%)
17(73.9%)
19(86.4%)
0.46
Topical corticosteroids, n(%)
23(100.0%)
21(95.5%)
0.49
Topical vitamin D analogue, n(%)
14(60.9%)
13(59.1%)
1.00
Salicylic acid, n(%)
7(30.4%)
4(18.2%)
0.49
LCD, n(%)
9(39.1%)
7(31.8%)
0.76
Sun exposure (hour/week)
9.61±10.5
14.95±9.01
0.07
Dietary vitamin D (IU/week)
191.47±134.67
386.39±680.77
0.19
PASI
4.68±3.12
4.21±2.53
0.58
Serum 25(OH)D level (ng/mL)
24.77±5.42
24.13±7.74
0.75
Vitamin D status classification
0.24
Deficiency (<20 ng/ml), n(%)
4(17.4%)
8(36.4%)
Insufficiency (21–29 ng/ml), n(%)
16(69.6%)
10(45.5%)
Adequacy (>30 ng/ml), n(%)
3(13.0%)
4(18.2%)
Parathyroid hormone level (pg/mL)
62.36±25.04
56.47±23.36
0.42
Calcium level (mg/dL)
9.03±0.36
8.94±0.36
0.40
Phosphorus level (mg/dL)
3.59±0.48
3.72±0.54
0.41
CRP level (mg/L)
6.94±6.65
3.7±4.44
0.07
Creatinine level (mg/dL)
0.84±0.20
0.89±0.29
0.49
Albumin level (mg/L)
4.04±0.43
4.11±0.24
0.51
Continuous data are mean ± standard deviation (SD); using the serum circulating 25-hydroxyvitamin D [25(OH)D] level, BMI: body mass index, LCD: Liquor Carbonis Detergens, PASI: Psoriasis Area and Severity Index, and CRP: C-reactive protein.
